{"id":"W4361190864","doi":"10.1158/1078-0432.ccr-22-2535","title":"A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Saskatchewan Cancer Agency; Centre hospitalier de l'Université Laval; Saskatoon Medical Imaging; University of Saskatchewan; Centre hospitalier universitaire de Québec; Royal University Hospital","funders":"National Institute of Neurological Disorders and Stroke; Canadian Institutes of Health Research; Saskatchewan Health Research Foundation; National Cancer Institute; Genome Canada","keywords":"Bispecific antibody; EPH receptor A2; Cancer; Medicine; Antibody; Cancer therapy; Epidermal growth factor receptor; Cancer research; Antibody therapy; Oncology; Internal medicine; Immunology; Monoclonal antibody; Receptor","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008733919,0.0007546476,0.0004381124,0.0006466296,0.0002372629,0.0004698967,0.0003886946,0.0004069302,0.001110565],"category_scores_gemma":[0.0003734881,0.0002790294,0.0002895902,0.0003248695,0.000281671,0.0003546498,0.0006511506,0.0006098368,0.0006123293],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004246649,"about_ca_system_score_gemma":0.0004587192,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002111362,"about_ca_topic_score_gemma":0.0006117113,"domain_scores_codex":[0.9993312,0.0001282215,0.00004588992,0.0001462397,0.0002588732,0.00008964902],"domain_scores_gemma":[0.9997956,0.00002383767,0.00006294161,0.00004041076,0.00004845685,0.00002874225],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00008291185,0.00006493721,0.0004889579,0.00004716391,0.0000150038,0.00005321536,0.00002084188,0.000870698,0.986222,0.000753666,0.0002072179,0.01117333],"study_design_scores_gemma":[0.00001248727,0.0002619864,0.0006275115,0.000005627815,0.0000229239,0.0002048732,0.00000692297,0.003700438,0.9899866,0.0001399667,0.005021495,0.000009245424],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.672837,0.004450466,0.3107427,0.0005428672,0.000123375,0.0008546007,0.000761005,0.001006785,0.008681134],"genre_scores_gemma":[0.8542525,0.002222006,0.1360505,0.0003065807,0.00003447941,0.0004973682,0.0008297748,0.0001251177,0.00568166],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001110565,"threshold_uncertainty_score":0.004618943,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.700667143084389,"score_gpt":0.6785639125598978,"score_spread":0.02210323052449126,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}